← Back to Search

Corticosteroid

Pomalidomide + PLD + Dexamethasone for Multiple Myeloma

Phase 1 & 2
Waitlist Available
Led By James R Berenson, MD
Research Sponsored by Oncotherapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of a combination of three different drugs, pomalidomide, pegylated liposomal doxorubicin, and dexamethasone when used to treat relapsed (the disease came back) or refractory (the disease did not respond to past treatment) multiple myeloma. Different dosages (amount of study drug) of pomalidomide are first being tested to determine if there are any side effects or risks associated with combining this study drug with the other two listed. Once the optimal dose is decided on, the study will change its focus to determining the effectiveness of the study drug in this combination.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
MTD of Pomalidomide
Overall Response Rate
Secondary outcome measures
Duration of Response
Number of Patients with Adverse Events
Overall Survival
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pomalidomide + PLD + DexamethasoneExperimental Treatment3 Interventions
Pomalidomide + Pegylated Liposomal Doxorubicin + Dexamethasone in an open label, dose escalation study
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pomalidomide
FDA approved
Doxorubicin
FDA approved
Dexamethasone
FDA approved

Find a Location

Who is running the clinical trial?

OncotherapeuticsLead Sponsor
22 Previous Clinical Trials
873 Total Patients Enrolled
21 Trials studying Multiple Myeloma
850 Patients Enrolled for Multiple Myeloma
Celgene CorporationIndustry Sponsor
444 Previous Clinical Trials
58,166 Total Patients Enrolled
73 Trials studying Multiple Myeloma
10,479 Patients Enrolled for Multiple Myeloma
James R Berenson, MDPrincipal InvestigatorOncotherapeutics
8 Previous Clinical Trials
348 Total Patients Enrolled
8 Trials studying Multiple Myeloma
348 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
2012. "Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01541332.
All > Myeloma
~5 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top